Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Clinical Trials
16
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
8
50.0%
Not yet recruiting
1
6.3%
Recruiting
1
6.3%
Terminated
2
12.5%
Unknown
1
6.3%
Withdrawn
3
18.8%
No approval data available
- Providence Medical Technology has enrolled the first patients in a prospective randomized controlled trial evaluating the CORUS-LX System for treating degenerative lumbosacral disease. - The multi-center superiority trial compares CORUS-LX combined with interbody fusion and pedicle screws against the current gold standard of interbody fusion with pedicle screws alone. - The study builds on the company's FUSE trial, which demonstrated superior composite fusion rates when adding CORUS PCSS to anterior cervical fusion procedures. - The primary endpoint aims to demonstrate superior 12-month composite fusion rates for L4-S1 lumbar fusion patients, with follow-up through 2027.
- Elutia Inc. has appointed Pete Ligotti as Chief Commercial Officer to lead the commercialization of NXT-41x, a next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgery. - NXT-41x targets the breast reconstruction market where over 162,000 procedures are performed annually in the U.S., yet infection rates of 15% to 20% persist despite biological surgical mesh being standard in over 80% of cases. - The biologics for breast reconstruction market represents an estimated $1.5 billion total U.S. market opportunity, with Elutia anticipating FDA clearance for NXT-41x in 2027. - Ligotti brings twenty years of commercial execution experience in complex surgical markets, including building Integra LifeSciences' plastic and reconstructive surgery operation and scaling specialty surgical businesses to over $180 million in revenue.
- Spineway's subsidiary Spine Innovations received GMED approval for a new production line dedicated to LP-ESP and CP-ESP intervertebral disc prostheses, marking a significant strategic milestone for the company. - The new production facility in La Rochelle includes a clean room for injection operations and doubles Spineway's manufacturing capacity while securing their supply chain. - First LP-ESP prostheses entered production last month with implants from the new line expected to be available by the end of July 2025. - The three-year development project strengthens Spineway's position in less invasive spine treatments and reinforces their industrial commitment in France.
- Globus Medical's ExcelsiusFlex robot received FDA 510(k) clearance, designed for stereotactic guidance in orthopedic joint or spine surgeries, marking a significant advancement in surgical technology. - The ExcelsiusFlex robot was also approved for use with the Actify 3D total knee system, integrating cementless reconstruction with operative efficiency and anatomical fit for improved knee replacement outcomes. - Globus Medical launched the Adira extreme lateral interbody fusion plate system, enhancing its lateral interbody portfolio with a simplified insertion workflow and rigid coupling mechanism.
